Comparing the current results to its competitors, Acumen Pharmaceuticals Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 11.12 %, recorded in the same quarter.
Acumen Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The competitive landscape for Alzheimer's disease therapies includes Roche Holding AG (and its subsidiary Genentech, Inc.), Wavebreak Therapeutics, Inc., AbbVie, AC Immune SA, Alector, Anavex Life Sciences Corp., Annovis Bio, Inc., Biogen, Biohaven Pharmaceuticals, Inc., Cassava Sciences, Inc., Denali, Eisai, Johnson & Johnson (including Janssen Inc.), H. Lundbeck A/S, Lighthouse Pharmaceuticals, Inc., and Takeda Pharmaceutical Co. Ltd. Payors may also impact competition through mechanisms such as formularies, step edits, prior authorizations, and reimbursement decisions, which influence market access and product utilization.
July 29, 2024
: Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on Alzheimer s disease treatments, has initiated a Phase 1 study for its investigational drug, sabirnetug (ACU193). This article outlines the significance of the study, the drug s mechanism of action, and its potential implications for treating early Alzheimer s disease.Acumen Pharmaceuticals, Inc. announced a significant milestone on July 29, 2024, as it dosed the first subject in a Phase 1 pharmacokinetic (PK) comparison study for its investigational drug, sabirnetug (ACU193). This study is particularly noteworthy as it aims to evaluate the pharmacokinetics of a subcutaneous formulation of sabirnetug in comparison to its int...
April 4, 2024
In a collaborative and palpable effort to tackle the pervasive and debilitating effects of Alzheimer s Disease (AD), Acumen Pharmaceuticals and Lonza have signed an agreement to advance the production and clinical development of a potential new therapeutic agent, sabirnetug (ACU193). The announcement was made on April 4, 2024, from the companies respective headquarters in Charlottesville, VA, and Basel, Switzerland.This collaboration represents an important step forward in Alzheimer’s Disease treatment, as both corporations possess considerable expertise and resources in pharmaceutical development. Acumen Pharmaceuticals, a dedicated clinical-stage biopharmaceutical company, has been actively working on n...
March 21, 2024
In a groundbreaking move within the field of Alzheimer s disease research, Acumen Pharmaceuticals is poised to unveil compelling insights, including fluid biomarker data, during an Emerging Science Session at the prestigious American Academy of Neurology Annual Meeting. This eagerly anticipated event not only highlights the company s commitment to scientific progression but also marks a crucial milestone towards the Phase 2 trial initiation for their pioneering drug, Sabirnetug. This article will outline the significant facts surrounding Acumen Pharmaceuticals endeavors and evaluate their impact on the company s future prospects.1. Illuminating Findings from the Emerging Science Session:By participating in ...
February 21, 2024
Exploring the Efficacy of Sabirnetug (ACU193) in Early Alzheimer s Disease: Insights from Phase 1 INTERCEPT-AD StudyAlzheimer s disease (AD) is a devastating neurodegenerative disorder affecting millions of individuals worldwide. Despite extensive research, there is currently no cure for AD, and available treatments only provide temporary symptomatic relief. Therefore, there is an urgent need for the development of novel therapeutic approaches to slow down or halt the progression of this debilitating condition. Recently, Acumen Pharmaceuticals announced their groundbreaking findings from the Phase 1 INTERCEPT-AD study, which examined the effects of their drug candidate, Sabirnetug (ACU193), on cerebrospinal ...
Grifols SA operates a business model that focuses on plasma-derived medicine production and commercialization, including plasma collection, testing, and fractionation, as well as the development of diagnostic equipment and transfusion medicine. Their core activities involve the extraction of plasma, transforming it into life-saving therapies, and distributing them worldwide to healthcare providers.
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
Sources:
Acumen Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Acumen Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
